Novo Nordisk Invests $507 Million in Irish Factory for Wegovy Production

Novo Nordisk plans to invest $507 million in upgrading its factory in Ireland to produce the popular Wegovy weight-loss medication for international markets. Bloomberg posted on X, highlighting the company's strategic move to expand its production capabilities outside the United States. This investment underscores Novo Nordisk's commitment to meeting the growing global demand for its weight-loss drug. The Irish facility will play a crucial role in the company's efforts to increase its supply chain efficiency and ensure the availability of Wegovy in various markets worldwide. The expansion is part of Novo Nordisk's broader strategy to enhance its manufacturing infrastructure and support its long-term growth objectives.